Anti-Cytokeratin 10/13 Purified

*Ivanyi D, Minke JM, Hageman C, Groeneveld E, van Doornewaard G, Misdorp W: Cytokeratins as markers of initial stages of squamous metaplasia in feline mammary carcinomas. Am J Vet Res. 1993 Jul;54 (7) :1095-102., URL: https://pubmed.ncbi.nlm.nih.gov/7690208/, *Ivanyi D, Minke JM, Hageman C, Groeneveld E, van Doornewaard G: Patterns of expression of feline cytokeratins in healthy epithelia and mammary carcinoma cells. Am J Vet Res. 1992 Mar;53 (3) :304-14., URL: https://pubmed.ncbi.nlm.nih.gov/7690208/, *Kozaki M, Nakamura Y, Iguchi M, Kano R, Watanabe S, Fujiwara K, Hasegawa A: Immunohistochemical analysis of cytokeratin expression in dog skin. J Vet Med Sci. 2001 Jan;63 (1) :1-4. , URL: https://www.ncbi.nlm.nih.gov/pubmed/11217052?dopt=

The mouse monoclonal antibody DE-K13 reacts with cytokeratin 10 (56.5 kDa) and cytokeratin 13 (53 kDa) . Cytokeratins are members of intermediate filaments subfamily of intracellular proteins, represented in epithelial tissues. DE-K13 recognizes only cytokeratin 13 on formalin-fixed, paraffin-embedded tissue sections.

Immunohistochemistry (paraffin sections) : Standard ABC technique (DAB+), recommended dilution: 10 μg/ml (1:100), positive tissue: tonsil. Pretreatment: 0.1% pepsin in 0.1 M HCl for 30 min at room temperature or Target Retrieval Solution - High pH. The antibody DE-K13 reacts exclusively with Cytokeratin 13. Immunohistochemistry (frozen sections) : Use at an assay dependent dilution. Western blotting: recommended dilution: 1-3 μg/ml.